A modified experimental model of malignant pleural disease induced by lung Lewis carcinoma (LLC) cells

Author(s)

Pagliarelli Acencio, Milena Marques ^[1] ; Puka, Juliana ^[1] ; Marchi, Evaldo ^{[1, 2]} ; Antonangelo, Leila ^{[1, 3, 4]} ; Terra, Ricardo Mingarini ^[5] ; Vargas, Francisco Suso ^[1] ; Capelozzi, Vera Luiza ^[1] ; Teixeira, Lisete Ribeiro ^[1]

Affiliation

^[1] Univ Sao Paulo, Sch Med, Heart Inst InCor, Pleura Lab, Pulm Div, BR-05403000 Sao Paulo - Brazil

^[2] Med Coll Jundiai, Sao Paulo - Brazil

^[3] Univ Sao Paulo, Sch Med, Hosp Clin, Dept Pathol, Clin Lab, BR-05403000 Sao Paulo - Brazil

^[4] Univ Sao Paulo, Sch Med, Hosp Clin, Dept Pathol, LIM 03, BR-05403000 Sao Paulo - Brazil

^[5] Univ Sao Paulo, Sch Med, Heart Inst InCor, Div Thorac Surg, BR-05403000 Sao Paulo - Brazil

• Document type: Journal article
• Source: JOURNAL OF TRANSLATIONAL MEDICINE; v. 13, SEP 15 2015.
• Web of Science Citations: 2

Abstract

Background: Malignant pleural effusion resulting mainly from pleural metastases of lung adenocarcinoma has clinical relevance, being a sign of poor prognosis and low life expectancy. Experimental models can mimic the human condition, contributing to advances in current understanding of the mechanisms patients' pleural fluid accumulation and possible therapeutic strategies. The objective of this study is to evaluate the role of different concentrations of Lewis lung carcinoma cells (LLC cells) at the time of induction of experimental MPE and the main effects on survival of animals. Methods: C57BL/6 mice received intrapleural injection of 0.1, 0.5 or 1.5 x 10(5) LLC cells and survival curve, biochemical and pathological analyses of pleural fluid and tissue were analyzed. Results: Evaluation of weight loss, mobility and survival showed that animals that received 0.5 x 10(5) cells maintained more stable condition up to day 14 and a gain of 6 days survival over mice that received the highest concentration. Conclusion: This study may allow a better understanding the mechanisms involved in the development of malignant pleural effusion and it may be promising in evaluating therapy to avoid recurrence, as the best time to indicate pleurodesis or target therapies. (AU)

• FAPESP's process: 13/11148-9 - Biomecular profile of experimental malignant pleural effusion: frequency of mutations and targeted therapies impact
• Grantee: Lisete Ribeiro Teixeira
• Support Opportunities: Regular Research Grants